Sight Sciences/$SGHT
1D1W1MYTD1Y5YMAX
About Sight Sciences
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
- Ticker
- $SGHT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 186
- Headquarters
- Menlo Park, United States
- Website
- www.sightsciences.com
Sight Sciences Metrics
BasicAdvanced
$453M
-
-$0.56
2.42
-
Price and volume
Market cap
$453M
Beta
2.42
52-week high
$9.24
52-week low
$3.19
Average daily volume
252K
Financial strength
Current ratio
4.949
Quick ratio
4.446
Long term debt to equity
59.457
Total debt to equity
79.355
Interest coverage (TTM)
-3.82%
Profitability
EBITDA (TTM)
-19.264
Gross margin (TTM)
87.96%
Net profit margin (TTM)
-35.69%
Operating margin (TTM)
-23.60%
Effective tax rate (TTM)
0.10%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
-10.84%
Return on equity (TTM)
-48.42%
Valuation
Price to revenue (TTM)
5.273
Price to book
8.5
Price to tangible book (TTM)
8.5
Price to free cash flow (TTM)
-18.843
Free cash flow yield (TTM)
-5.31%
Free cash flow per share (TTM)
-0.436
Growth
Revenue change (TTM)
9.27%
Earnings per share change (TTM)
-42.02%
3-year revenue growth (CAGR)
0.76%
3-year earnings per share growth (CAGR)
-27.67%
What the Analysts think about Sight Sciences
Analyst ratings (Buy, Hold, Sell) for Sight Sciences stock.
Sight Sciences Financial Performance
Revenues and expenses
Sight Sciences Earnings Performance
Company profitability
Sight Sciences News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.